Foghorn Therapeutics shares preclinical cancer data at AACR meeting

nl.investing.com (Dutch)

Foghorn Therapeutics will present preclinical cancer data at the AACR meeting, focusing on novel drug candidates. The company will showcase data for FHD-909, a SMARCA2 inhibitor for SMARCA4-mutant cancers, and FHT-171, a CBP degrader for ER+ breast cancer. These presentations highlight Foghorn's work on targeting the chromatin-regulating system for cancer therapies.


With a significance score of 1.5, this news ranks in the top 35% of today's 29093 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Foghorn Therapeutics shares preclinical cancer data at AACR meeting | News Minimalist